Question

1. Which of the following best describes recent findings comparing bariatric surgery to GLP-1 RA for the management of obesity?
A. Semaglutide was the most commonly used GLP-1 RA.
B. Patients undergoing bariatric surgery lost similar weight as those receiving GLP-1 RA therapy.
C. Maximum weight loss was achieved with GLP-1 RA use after bariatric surgery.
D. Overall costs were higher for the bariatric surgery cohort.

2. What was the most common vitamin deficiency documented in a recent retrospective trial evaluating nutritional deficiencies during GLP-1 RA therapy?
A. Vitamin D
B. Vitamin A
C. Vitamin E
D. Vitamin K

3. Semaglutide (Wegovy) was recently approved by the FDA to treat what gastrointestinal condition?
A. Ulcerative colitis
B. Crohn's disease with fistula
C. Cirrhosis with esophageal varices
D. Metabolic-associated steatohepatitis

4. Which of the following best describes maridebart cafraglutide's mechanism of action?
A. GLP-1 receptor agonist and GIP receptor agonist
B. GLP-1 receptor agonist and GIP receptor antagonist
C. GLP-1 receptor antagonist and GIP receptor agonist
D. GLP-1 receptor antagonist and GIP receptor antagonist

5. Nutritional deficiencies were detected more often when patients receiving GLP-1 RA were cared for by a
A. Nutritionist
B. Pharmacist
C. Dietitian
D. Nurse Practitioner

6. Which of the following is true regarding a recent study evaluating GLP-1 RA and testosterone therapies on overall testosterone concentrations?
A. Testosterone increased the risk of myocardial infarction compared to GLP-1 RA patients.
B. Tirzepatide produced greater increases in overall testosterone concentrations compared to testosterone alone.
C. Semaglutide produced the highest increases in testosterone concentrations among the GLP-1 RAs.
D. Testosterone produced an increased risk of testicular cancer compared to GLP-1 RAs.

7. Which of the following statements most accurately describes the recent study evaluating cancer risk with GLP-1 RA therapy?
A. Decreased risk of colorectal cancer was the primary benefit among GLP-1 RA users.
B. Patients with breast cancer had higher survival rates if detected while on GLP-1 RA therapy.
C. Overall cancer risk was similar between GLP-1 RA users and nonusers.
D. Decreased ovarian cancer was observed in patients receiving GLP-1 RA compared to nonusers.

8. The investigational antiobesity agent maridebart cafraglutide would have what advantage over currently approved therapies such as semaglutide or tirzepatide?
A. Maridebart cafraglutide can be given orally.
B. The average weight loss with maridebart cafraglutide is greater than with currently approved agents.
C. Gastrointestinal adverse effects of maridebart cafraglutide are minimal, leading to better tolerability.
D. Maridebart cafraglutide may be dosed less frequently (e.g., once monthly).

9. Cagrilintide exerts its antiobesity effects primarily via which mechanism of action?
A. Amylin analogue binding to amylin receptors
B. Adrenocorticotropic hormone stimulation
C. Glucagon agonism with secondary GLP-1 agonist
D. Glucose-dependent insulinotropic polypeptide agonist

10. Cagrilintide was recently evaluated with semaglutide in 2 phase 3 trials (non-T2DM and T2DM populations, respectively). Which of the following is the most accurate statement regarding gastrointestinal tolerability of this agent in the studies?
A. Participants in the T2DM cohort were given prophylactic antinausea medications, which led to less nausea/vomiting.
B. Participants in the non-T2DM cohort had significantly more gastroparesis than the T2DM cohort, leading to more nausea and vomiting.
C. The combination of the drugs was titrated starting at the lowest doses, leading to primarily mild-to-moderate gastrointestinal adverse effects.
D. Semaglutide doses were capped at 1 mg weekly in the T2DM study, leading to less overall hypoglycemia.

Answer 1

1. D
2. A
3. D
4. A
5. B
6. A
7. C
8. D
9. A
10. C